Rabbits possess a robust and unique immune system that generates antibodies with superior specificity, affinity and diversity compared to rodents. This makes them highly recommended for producing high-quality antibodies. In the dynamic field of pharmaceutical development, the need for high precision and rigorous safety validation is critical to ensuring the efficacy and safety of new therapeutics.
Therefore, anti-idiotypic antibodies (anti-ID Abs) play a crucial role in this process by binding to therapeutic drugs in biological fluids, facilitating drug validation and safety evaluation. They are commonly used in pharmacokinetics (PK) and pharmacodynamics (PD) assays to assess drug efficacy and are instrumental in evaluating drug safety through anti-drug antibody (ADA) assays, which measure immunogenicity.
In this webinar, the expert speaker will provide a detailed overview of anti-ID abs, exploring their significance and applications. She will also delve into the reasons why rabbits are the preferred host for generating high-performance anti-ID abs and highlight the advantages that make them ideal for this purpose. Additionally, attendees will gain insights into the advanced techniques and methodologies to optimize the development of these crucial antibodies, enhancing therapeutic and diagnostic outcomes in the biopharmaceutical industry.
Register for this webinar today to discover why rabbits are the preferred choice for generating high-performance anti-ID Abs and learn advanced techniques to optimize antibody development.
Keywords: Drug Development, Antibody, Clinical Research, CRO, Animal Models, Monoclonal Antibody, Therapeutic Antibody Development, Pre-Clinical, Cell & Gene Therapies, Basic Research